Table 1.
Comparison of general data of patients in the TACE-125I group and the TACE-S group.
| Variable | Grading | TACE-125I groupn=32 | TACE-S groupn=26 | P value |
|---|---|---|---|---|
| Gender | Male | 27 (84.4) | 23 (88.5) | 0.947 |
| Female | 5 (15.6) | 3 (11.5) | ||
| Age | ≤60 | 17 (53.1) | 13 (50.0) | 1.000 |
| >60 | 15 (46.9) | 13 (50.0) | ||
| ECOG Score | 0 | 9 (28.1) | 12 (46.2) | 0.252 |
| 1 | 23 (71.9) | 14 (53.8) | ||
| Child-Pugh classification | Class A | 29 (90.6) | 20 (76.9) | 0.285 |
| Class B | 3 (9.4) | 6 (23.1) | ||
| Number of liver tumors | 1 | 10 (31.2) | 12 (46.2) | 0.373 |
| ≥2 | 22 (68.8) | 14 (53.8) | ||
| Maximum tumor diameter | <60 | 19 (59.4) | 18 (69.2) | 0.616 |
| ≥100 | 13 (40.6) | 8 (30.8) | ||
| Total tumor diameter | <100 | 24 (75.0) | 23 (88.5) | 0.335 |
| ≥100 | 8 (25.0) | 3 (11.5) | ||
| Tumor location | Single leaf | 8 (25.0) | 9 (34.6) | 0.610 |
| Futaba | 24 (75.0) | 17 (65.4) | ||
| PVTT type | IIa | 18 (56.2) | 17 (65.4) | 0.662 |
| IIb | 14 (43.8) | 9 (34.6) | ||
| APFs classification | Mild | 17 (53.1) | 13 (50.0) | 0.949 |
| Moderate | 11 (34.4) | 10 (38.5) | ||
| Severe | 4 (12.5) | 3 (11.5) | ||
| AFP(ng/ml) | <400 | 15 (46.9) | 16 (61.5) | 0.396 |
| ≥400 | 17 (53.1) | 10 (38.5) | ||
| TBL (g/L) | 21.51 (11.13) | 19.24 (11.71) | 0.453 | |
| ALB (μmol/L) | 38.77 (5.31) | 37.96 (4.54) | 0.540 | |
| PT(s) | 12.97 (1.17) | 13.30 (1.80) | 0.415 | |
| WBC(10×12/L) | 4.94 (1.87) | 5.31 (1.60) | 0.423 | |
| RBC(10×9/L) | 4.33 (0.50) | 4.17 (0.49) | 0.238 | |
| HGB(g/L) | 132.53 (15.83) | 130.12 (12.38) | 0.528 |
Unless otherwise indicated, data are presented as numbers of patients.
TACE, transarterial chemoembolisation; ECOG, Eastern Cooperative Oncology Group; PVTT, portal vein tumor thrombosis; AFP, alpha-fetoprotein; TBL, total bilirubin; ALB, albumin; PT, prothrombin time; WBC, white blood cell; RBC, red blood cell; HGB, haemoglobin.